Overview

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Status:
SUSPENDED
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of talectrectinib as treatment for Stage IV ILC with CDH1 mutation
Phase:
PHASE2
Details
Lead Sponsor:
Megan Kruse, MD
Collaborator:
AnHeart Therapeutics Inc.
Treatments:
taletrectinib